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advocacy program were involved in the creation of the Faces of Lung 
Cancer project. 
Methods: A previous project collected data from newly diagnosed and 
established patients as well as former clinical trial participants on their 
attitudes towards clinical trials for lung cancer patients. Results of this 
project indicated patients held misperceptions about clinical trials and 
their purpose. These data were collected and analyzed using a social 
marketing approach and the resultant intervention was a series of media 
products. The marketing mix for the intervention was reﬁned and based 
upon the narratives of eleven lung cancer patients who participated in 
a clinical trial, ﬁve caregivers of patients who had been on a trial, and 
four thoracic health care professionals. These individuals were inter-
viewed and photographed by a professional photographer with prior 
experience in photo-documentary work. 
Results: The ﬁnal media products include a framed photo exhibit, 
book, brochure, website (www.facesoﬂungcancer.com) and profes-
sional presentation. The book and photo exhibit are continuously 
evaluated for impact and satisfaction. Presently, results indicate the 
process of participating in the Faces of Lung Cancer project has had 
a positive impact on the lives of cancer patients and their caregivers. 
From the 90 evaluations received thus far, respondents agreed that lung 
cancer patients and their loved ones would beneﬁt from the project (M 
= 4.80, SD = 0.41), the essays were easy to read (M = 4.84, SD = 0.37), 
the Faces of Lung Cancer photo essay is a powerful tool for commu-
nicating important information (M = 4.80, SD = 0.41), and they would 
recommend the Faces of Lung Cancer exhibit to people they know (M 
= 4.88, 0.33). 
Conclusion: Evaluation of the Faces of Lung Cancer project indicates 
it is viewed as successful in terms of conveying a message of hope 
and increasing awareness. By including visual displays, in conjunction 
with patient interviews, the photo essay is able to generate and blend 
powerful information and images that provide a richer, more complete 
portrayal of the context of a patient’s experience.
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Introduction: According to several guidelines, Erythropoietic-Stimu-
lating Agents (ESAs) are indicated for treatment of chemotherapy-
induced anaemia (CIA), because they effectively increase haemoglo-
bin (Hb) concentrations, reduce the need for red blood cell (RBC) 
transfusions and improve quality-of-life. Darbepoetin alfa (DA), an 
ESA with a prolonged half-life, has been shown to be effective when 
administered in a dose of 500 ìg once every 3 weeks (Q3W), thereby 
allowing synchronisation of erythropoietic therapy with Q3W chemo-
therapy schedules [Canon et al, J Natl Cancer Inst 98: 273, 2006]. The 
aim of this study was to examine the pattern of use of DA Q3W in daily 
practice in Belgium and Luxembourg, and the adherence to guidelines 
in ESA treatment.
Methods: OASIS (Observational Aranesp® Survey to Investigate the 
q3w Schedule) was a nationwide, prospective observation of DA use 
in 41 oncology centres between April 2005 and January 2006. Adult 
patients with non-myeloid malignancies, who had received DA for CIA 
were included. Data on demographics, type of chemotherapy, baseline 
and evolution of Hb, occurrence of blood transfusion(s), timing of ad-
ministration of the chemotherapy and DA, tolerance and comfort of use 
were collected. Patients were followed from the start of ESA till one 
week after the last DA treatment, with a maximum of 16 weeks.
Results: 293 patients were included. Mean age was 63 years (range 
25-89), 51% were male, 263 patients had a solid tumour (NSCLC 
n=91; breast cancer n=64; and SCLC n=32; others n=76) and 30 had 
haematologic malignancies. 30.8% were non-metastatic tumours, 
62.4% were metastatic, and 6.8% were recurrent. 57% of patients had 
platinum containing chemotherapy (mainly lung cancer). Baseline Hb 
was between 10 and 11 g/dL in 50.9% of the patients, and between 9 
and 10 g/dL in 31.1%. In an analysis correcting for RBC transfusion 
(disregarding Hb values after ﬁrst transfusion), the crude haematopoi-
etic response rate was 53.6% in platinum treated patients, compared 
to 47.1% in non-platinum treated patients. A Hb level of 11 g/dL was 
reached in 68% of the patients (both platinum and non-platinum). The 
RBC transfusion rate was 26.6%, similar in platinum or non-platinum 
treated patients. 63.4% of the patients experienced a very good to 
satisfactory improvement of anemia related symptoms. The majority 
of the patients (69.6%) were treated in a Q3W chemotherapy schedule. 
The DA Q3W interval could be maintained in a substantial number of 
patients. The most important reason for not respecting the Q3W DA in-
terval was practical (mainly remain synchronized with chemotherapy). 
There were no unexpected safety concerns, with only 7 adverse and 3 
serious adverse events.
Conclusion: This prospective observation study conﬁrms the phase III 
study efﬁcacy and safety ﬁndings of Canon et al. in a broader commu-
nity setting. Adherence to guidelines is good, as ESA therapy is indeed 
started at a Hb threshold between 9 and 11 g/dL in more than 80% of 
the patients. The synchronisation of ESA therapy could be maintained 
in a substantial number of patients.
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Objective: To validate the Rapid Community Health Assessment 
Methodology (RCHA) for prioritization of community health problems 
(Eg: Tobacco And Cancer Control) in a rural community. 
Methods: 14 Villages of rural areas. Study Population: 34 Primary 
School Teachers from 10 randomly selected Primary Schools in 
above villages. (One Teacher each from Class I to V, in each School). 
Validation: Heads of households from 500 Households (50 per village, 
systematically sampled). DATA Self-Administered Questionnaires for 
Teachers, Interview Schedules for Heads of Households. Data Analy-
sis: with the help of EPI info program. 
Results: There was signiﬁcant correlation between the responses of 
the school teachers and heads of households on community health 
problems viz., (a) the prioritization of ten village problems(r=+0.77, 
